CLLS Upcoming Earnings (Q3 2023)
|Earnings Date:||Nov 02, 2023|
Current P/E* ratio: -0.96 | Price (Sep 29, 2023, EOD): $1.58
*The P/E ratio (price-to-earnings ratio) is a financial metric used to assess a company's stock valuation. It is calculated by dividing the stock price by its earnings per share. A higher ratio suggests higher investor expectations, while a lower ratio may indicate undervaluation. It helps investors evaluate potential investments, but it's essential to consider other factors too.
Last 3 Quarters for CLLS Premium
About Cellectis S.A.
Cellectis S.A., a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. It operates through two segments, Therapeutics and Plants. The company is developing UCART19, an allogeneic T-cell product candidate for the treatment of CD19-expressing hematologic malignancies, such as acute lymphoblastic leukemia; ALLO-501 and ALL... CLLS Profile
Top Fintech Company
featured in The Global Fintech Index 2020 as the top Fintech company of the country.